Economic evaluation of vaccination programs: The impact of herd-immunity

Medical Decision Making

Volumn 23, Issue 1, 2003, Pages 76-82

  Brisson, M ^a,b   Edmunds, W J ^a,b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b CITY UNIVERSITY   (United Kingdom)

Author keywords

Dynamic models; Externality; Infectious diseases; Modeling; Vaccination

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; IMMUNITY; INFECTION; MORBIDITY; VACCINATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CHICKENPOX; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; ENGLAND; HUMANS; IMMUNITY, HERD; INCIDENCE; INFANT; INFANT, NEWBORN; MASS IMMUNIZATION; MIDDLE AGED; MODELS, STATISTICAL; WALES;

EID: 0037245609     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0272989X02239651     Document Type: Article

References (26)

1. Elixhauser A, Halpern M, Schmier J, Luce BR. Health care cost-benefit analysis and cost-effectiveness analysis from 1991 to 1996: an updated bibliography. Med Care. 1998;36:MS1-145.
2. Mullins CD, Ogilvie S. Emerging standardization in pharmacoeconomics. Clin Ther. 1998;20:1194-202.
3. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996;313:275-83.
4. Commonwealth of Australia. Guidelines for pharmaceutical industry and preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including economic analyses. Canberra, Australia: Department of Health and Community Services; 1995.
5. Torrance GW, Blaker D, Detsky A, Kennedy W, Schubert F, Menon D, et al. Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics. Pharmacoeconomics. 1996;9:535-59.
6. Lovatt B. The United Kingdom guidelines for the economic evaluation of medicines. Med Care. 1996;34(suppl):DS179-81.
7. Beutels P, Edmunds WJ, Antonanzas F, de Wit GA, Evans D, Feilden R, et al. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics. 2002;20:1-7.
8. Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med. 1999;18:3263-82.
9. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. Oxford, UK: Oxford University Press; 1991.
10. Fine PE. Herd immunity: history, theory, practice. Epidemiol Rev. 1993;15:265-302.
11. Anderson RM, May RM. Vaccination and herd immunity to infectious diseases. Nature. 1985;318:323-9.
12. Nokes DJ, Anderson RM. The use of mathematical models in the epidemiological study of infectious diseases and in the design of mass immunization programmes. Epidemiol Infect. 1988;101:1-20.
13. Rothberg M, Bennish ML, Kao JS, Wong JB. Do the benefits of varicella vaccination outweigh the long-term risks? A decision-analytic model for policymakers and pediatricians. Clin Infect Dis. 2002;34:885-94.
14. Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect. 2000;125:651-9.
15. Brisson M, Edmunds WJ, Gay NJ. Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J Med Virol. In press.
16. Brisson M, Edmunds WJ. The cost-effectiveness of varicella zoster virus (VZV) vaccination in Canada. Vaccine. 2002;20:1113-25.
17. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-38.
18. Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001;127:305-14.
19. Brisson M, Edmunds WJ. Epidemiology of varicella-zoster virus in England and Wales. J Med Virol. In press.
20. Atkinson WL, Orenstein WA, Krugman S. The resurgence of measles in the United States, 1989-1990. Annu Rev Med. 1992;43:451-63.
21. Cochi SL, Preblud SR, Orenstein WA. Perspectives on the relative resurgence of mumps in the United-States. Am J Dis Child. 1988;142:499-507.
22. Chen RT, Weierbach R, Bisoff Z, et al. A "post-honeymoon period" measles outbreak in Muyinga sector, Burundi. Int J Epidemiol. 1994;23:185-93.
23. Panagiotopoulos T, Antoniadou I, Valassi-Adam E. Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review. BMJ. 1999;319:1462-7.
24. Bailey NJT. The Mathematical Theory of Infectious Diseases and Its Application. London: Griffin; 1975.
25. Schenzle D. An age-structured model of pre- and post-vaccination measles transmission. IMA J Math Appl Ned Biol. 1984;1:169-91.
26. Burden RL, Faires JD. Numerical Analysis. Boston: PWS-Kent; 1993.